These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 20731080)

  • 1. Hepatitis C information.
    Proj Inf Perspect; 2010 Feb; (50):8-10. PubMed ID: 20731080
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenomics. Gene variants affect hepatitis C treatment, but link is elusive.
    Wapner J
    Science; 2010 Oct; 330(6004):579. PubMed ID: 21030622
    [No Abstract]   [Full Text] [Related]  

  • 3. [IL28 (interferon lambda3) gene polymorphisms and response to IFN-alpha treatment in patients infected with hepatitis virus C].
    Labie D; Gilgenkrantz H
    Med Sci (Paris); 2010 Mar; 26(3):225-6. PubMed ID: 20346265
    [No Abstract]   [Full Text] [Related]  

  • 4. [IL-28B polymorphism and hepatitis C: impact on viral clearance--prolonged, spontaneous and after treatment with antiviral drugs].
    Halfon P; Cacoub P
    Rev Med Interne; 2011 May; 32(5):271-4. PubMed ID: 21126807
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype.
    Thompson AJ; Muir AJ; Sulkowski MS; Patel K; Tillmann HL; Clark PJ; Naggie S; Fellay J; Ge D; McCarthy JJ; Goldstein DB; McHutchison JG
    Hepatology; 2010 Dec; 52(6):2243-4. PubMed ID: 20890887
    [No Abstract]   [Full Text] [Related]  

  • 6. IL-28B polymorphism and response to anti-hepatitis C therapy.
    Abbas Z
    J Pak Med Assoc; 2011 Jul; 61(7):621-2. PubMed ID: 22204230
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatitis C virus infection and genetic susceptibility to therapy.
    Sibbing B; Nattermann J
    J Gastrointestin Liver Dis; 2011 Dec; 20(4):397-406. PubMed ID: 22187706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL28B polymorphism and the control of hepatitis C virus infection: ready for clinical use?
    Orlent H; Reynaert H; Bourgeois S; Dideberg V; Adler M; Colle I; De Maeght S; Laleman W; Michielsen P; Moreno C; Mulkay JP; Stärkel P; Delwaide J;
    Acta Gastroenterol Belg; 2011 Jun; 74(2):317-22. PubMed ID: 21861317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reaping the early harvest of the genomics revolution.
    Chung RT
    Gastroenterology; 2010 May; 138(5):1653-4. PubMed ID: 20332044
    [No Abstract]   [Full Text] [Related]  

  • 10. Liver transplantation and hepatitis C: will understanding the interleukin-28B polymorphisms improve outcomes?
    McCaughan GW; Shackel NA; Bowen DG
    Liver Transpl; 2011 Mar; 17(3):219-21. PubMed ID: 21384503
    [No Abstract]   [Full Text] [Related]  

  • 11. Misplaced advocacy: What does better hepatitis C treatment really mean?
    Tyndall M
    CMAJ; 2015 Oct; 187(15):1111-1112. PubMed ID: 26243815
    [No Abstract]   [Full Text] [Related]  

  • 12. The importance of IL28B genotype in hepatitis C virus-associated liver transplantation.
    Lange CM
    Liver Int; 2013 Feb; 33(2):169-71. PubMed ID: 23295049
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of the treatment-experienced patient infected with hepatitis C virus genotype 1: options and considerations.
    Khalid O; Bacon BR
    Clin Liver Dis; 2011 Aug; 15(3):573-83. PubMed ID: 21867937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus viral assays in the direct-acting antiviral era.
    Vierling JM
    Clin Liver Dis; 2013 Feb; 17(1):27-45. PubMed ID: 23177281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C treatment in an urban population.
    Dela Cruz AC; Engelson E; Ionescu G; Dubrovskaya V; Kotler D
    Hepatology; 2010 Oct; 52(4):1524-5. PubMed ID: 20815014
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prediction of anti-viral therapy and host factors].
    Umemura T
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():184-8. PubMed ID: 26845927
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients.
    Nelson DR
    Liver Int; 2011 Jan; 31 Suppl 1():53-7. PubMed ID: 21205138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of hepatocellular carcinoma and response to interferon therapy in HCV-infected patients: effect of factors associated with the therapeutic response and incidence of HCC.
    Toyoda H; Kumada T
    Liver Int; 2012 Jul; 32(6):1029-31. PubMed ID: 22314231
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of IL-28B polymorphism on outcome in patients with hepatitis C after liver transplantation.
    Neumann U
    Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):429-31. PubMed ID: 21780887
    [No Abstract]   [Full Text] [Related]  

  • 20. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation.
    Eurich D; Boas-Knoop S; Ruehl M; Schulz M; Carrillo ED; Berg T; Neuhaus R; Neuhaus P; Neumann UP; Bahra M
    Liver Transpl; 2011 Mar; 17(3):289-98. PubMed ID: 21384511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.